Explore more topics
SEC Form 4 research

Prelude Therapeutics Inc insider transactions

Inspect Prelude Therapeutics Inc's public SEC insider acquisitions and sales, reporting owners and source receipts.

As of 2026-10-15T08:02:39.132Z

Issuer CIK
0001678660
Reporting owners
34
Officers and directors
14
Jump to a section

What is a Form 4?

Animation: what a Form 4 is, shown with one real example. Sonic Automotive (SAH) reporting owner Paul P. Rusnak bought 13,701 shares at $59.78 on Wednesday, October 7, 2026, transaction code P, an open-market purchase (S is a sale and A is an award from the company). A timeline marks the SEC's two-business-day filing deadline, which ends Friday, October 9. The SEC accepted the Form 4 at 4:33:21 PM ET on October 9, and NexusTrade treats it as public one minute later, at 4:34:21 PM ET. A lamp for NexusTrade's InsiderTrades indicator stays off from the trade date until that moment, then counts one purchase worth 13,701 × $59.78 = $819,045.78.
In this example the shares were bought on Oct 7, 2026, and NexusTrade's InsiderTrades indicator can count the purchase starting at 4:34:21 PM ET on Oct 9, one minute after the SEC accepted the Form 4.

A Form 4 is the SEC filing a company insider, such as an officer, director or 10% owner, uses to report a trade in the company's stock, generally within two business days. The animation follows one real filing as an example: Paul P. Rusnak's purchase of Sonic Automotive (SAH) shares on October 7, 2026.

The same reading applies to every row on this page. The trade date is when the shares changed hands. The available date is when NexusTrade treats the filing as public, and a NexusTrade InsiderTrades indicator counts a purchase (code P) or sale (code S) only from that moment. Code A awards are not counted as purchases.

Recent insider disclosures

This table includes purchases, sales and awards in the public filing record. Awards and open-market purchases are distinct transaction codes. For historical research, use the public availability date to determine when the transaction was knowable.

Read code P as a purchase, S as a sale and A as an award. An award is an acquisition, but it is not an open-market purchase. Open the filing receipt to check the transaction details.

Show the table · 0 rows, 7 columns

Scroll sideways to compare all columns. Select a heading to sort.

No records are available for this view.

Most recent 90-day source activity, up to 50 rows. No rows means no matching recent records, not no historical activity.

Officers and directors in the directory

Show the table · 22 rows, 3 columns

Scroll sideways to compare all columns. Select a heading to sort.

OrbiMed Genesis GP LLC0001808744218
Huang Jane00016839131
ORBIMED CAPITAL LLC0001157524113
Vaddi Krishna000182463315
Chardonnet Laurent000132901047
Combs Andrew00018250056
Lim Bryant David00017528887
Dier Mardi000157459163
Mauro David J000162117231
Bonita David P000157245179
667, L.P.00015511392,118
Baker Bros. Advisors (GP) LLC00015805752,197
BAKER BROS. ADVISORS LP00012635082,370
Baker Brothers Life Sciences LP00013633642,127
BAKER FELIX00010879404,174
BAKER JULIAN00010879394,416
Morosini Deborah00018246257
ORBIMED ADVISORS LLC00010559511,020
OrbiMed Capital GP VI LLC0001682115194
Pierce Christopher00018246317
Piper Brian00016659247
Scherle Peggy000182463217
OrbiMed Genesis GP LLC ↗Huang Jane ↗ORBIMED CAPITAL LLC ↗Vaddi Krishna ↗Chardonnet Laurent ↗Combs Andrew ↗Lim Bryant David ↗Dier Mardi ↗Mauro David J ↗Bonita David P ↗667, L.P. ↗Baker Bros. Advisors (GP) LLC ↗BAKER BROS. ADVISORS LP ↗Baker Brothers Life Sciences LP ↗BAKER FELIX ↗BAKER JULIAN ↗Morosini Deborah ↗ORBIMED ADVISORS LLC ↗OrbiMed Capital GP VI LLC ↗Pierce Christopher ↗Piper Brian ↗Scherle Peggy ↗

Which transactions qualify for the company tracker

The company strategy uses verified officers and directors with qualifying acquisitions at this issuer. Other reporting owners may appear in source records without becoming strategy signals.

Strategy eligibility is held while filing coverage is unresolved.

Historical follower simulations are separate from these source transactions. They do not establish live trading results.